Submerge-Paper Deep Dive: NIPPV for COPD exacerbation (HAPPEN Trial)

Send us a text

🚑 PICO Breakdown: The HAPPEN Trial on NPPV for COPD 🫁

P - Population:
Patients with acute exacerbation of COPD and persistent hypercapnia (PaCO₂ > 45 mmHg) after 6 hours of low-intensity NPPV.
👥 300 patients (Mean Age: 73 years, 68% Male)

I - Intervention:
High-Intensity NPPV - Tidal volume of 10-15 mL/kg using higher inspiratory positive airway pressure (IPAP).

C - Comparison:
Low-Intensity NPPV - Tidal volume of 6-10 mL/kg using lower IPAP.

O - Outcome:

• 🌟 65% ↓ Risk of meeting criteria for intubation (4.8% vs. 13.7%, p=0.004)
• ❌ No significant difference in actual intubation rates (3.4% vs. 3.9%)
• 🤢 More abdominal distension with high-intensity NPPV (37% vs. 25%)

💡 Clinical Pearl:
High-intensity NPPV may delay progression to severe respiratory failure but requires careful monitoring of side effects.

Reference: Luo Z, Li Y, Li W, et al. Effect of High-Intensity vs Low-Intensity Noninvasive Positive Pressure Ventilation on the Need for Endotracheal Intubation in Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease: The HAPPEN Randomized Clinical Trial. JAMA. 2024;332(20):1709-1722. doi:10.1001/jama.2024.15815.